GSK plc (LON:GSK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,760.50
-12.00 (-0.68%)
Nov 20, 2025, 4:29 PM BST
-0.68%
Market Cap71.22B
Revenue (ttm)32.17B
Net Income (ttm)5.49B
Shares Out4.02B
EPS (ttm)1.33
PE Ratio13.34
Forward PE9.91
Dividend0.61 (3.41%)
Ex-Dividend DateNov 13, 2025
Volume4,732,544
Average Volume8,909,610
Open1,778.00
Previous Close1,772.50
Day's Range1,755.00 - 1,783.00
52-Week Range1,242.50 - 1,830.00
Beta0.23
RSI58.03
Earnings DateOct 29, 2025

About GSK plc

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]

Sector Healthcare
Founded 1715
Employees 68,629
Stock Exchange London Stock Exchange
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.

Financial Statements

News

GSK (GSK): CDC Updates Vaccination and Autism Information

GSK (GSK): CDC Updates Vaccination and Autism Information

5 hours ago - GuruFocus

GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch

GSK Completes Acquisition of BREXAFEMME NDA for U.S. Market Relaunch

1 day ago - GuruFocus

Global drugmakers rush to boost US presence as tariff threat looms

Global drugmakers are rushing to boost U.S. manufacturing and inventory as the Trump administration weighs a 100% tariff on imported branded and patented drugs.

2 days ago - Reuters

UK officials ‘working night and day to resolve NHS drug pricing row’

Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition The UK science minister has said officials are “working day and night” trying to...

3 days ago - The Guardian

The Best Healthcare Stock to Hold in Uncertain Times

Looking for a cheap, safe healthcare stock to buy? Take two shares of GSK and call me in the morning.

6 days ago - The Motley Fool

Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact

Kahn Brothers' Strategic Moves: GSK PLC Sees a -3.08% Impact

7 days ago - GuruFocus

GSK CEO among candidates considered for Diageo leadership: FT

Diageo (DEO) has weighed multiple candidates including outgoing GSK (GSK) CEO Emma Walmsley for its leadership role as CEO search frustrates investors. Read more here.

12 days ago - Seeking Alpha

GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025

GSK (GSK) Highlights Liver Disease Research Developments at AASLD 2025

13 days ago - GuruFocus

GSK Pharma shares fall over 2% as Q2 revenue fell 3.1% YoY to Rs 980 crore

GSK Pharma shares slipped over 2% in early trade on Friday after the company announced its second-quarter (Q2) results for...

13 days ago - Business Upturn

FDA Recognizes GSK's Dostarlimab for Rectal Cancer in Latest Voucher Pilot

FDA Recognizes GSK's Dostarlimab for Rectal Cancer in Latest Voucher Pilot

13 days ago - GuruFocus

GlaxoSmithKline India reports higher second-quarter profit on specialty medicine growth

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for its specialty medicine portfolio.

14 days ago - Reuters

GSK PLC (GSK) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance

GSK PLC (GSK) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance

15 days ago - GuruFocus

Q3 2025 GSK plc Earnings Call Transcript

Q3 2025 GSK plc Earnings Call Transcript

15 days ago - GuruFocus

3 Dividend Stocks for November 2025

This month's trio includes two ADRs.

16 days ago - Morningstar

We need clarity on big pharma’s tax breaks | Letters

Pharmaceutical giants like GSK should be more transparent about the generous tax breaks they get from the UK government, says Mike Lewis The outgoing chief executive of the pharmaceutical company GSK ...

16 days ago - The Guardian

GSK Shares Surge 4.9% on Strong Q3 Earnings and Raised 2025 Outlook

GSK Shares Surge 4.9% on Strong Q3 Earnings and Raised 2025 Outlook

21 days ago - GuruFocus

GSK plc (GSK) Q3 2025 Earnings Call Transcript

GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare...

22 days ago - Seeking Alpha

GSK (GSK) Surges on Strong Q3 Results and Improved Outlook

GSK (GSK) Surges on Strong Q3 Results and Improved Outlook

22 days ago - GuruFocus

GSK boss: Britain must reform drug pricing to become a life sciences superpower

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved GSK’s outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a “life sciences super...

22 days ago - The Guardian

GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View

GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

22 days ago - Nasdaq

GSK Stock Rises as Strong Performance Boosts Outlook

GSK Stock Rises as Strong Performance Boosts Outlook

22 days ago - GuruFocus

GSK Shares Leap 4% as Pharma Giant Boosts Guidance on Vaccine Breakthrough

GlaxoSmithKline plc (GSK), the pharmaceutical giant of the FTSE 100, shocked investors today with the second boost in its Full-Year profit expectations for this quarter, fuelled by blockbuster vaccine...

22 days ago - ABC Money

GSK rises on higher profit growth projected for 2025

GSK jumps after Q3 earnings beat and boosted 2025 outlook. Read more here.

22 days ago - Seeking Alpha